Search - tctmd.com

Displaying 281 - 300 of 449

Sort: Relevancy | Date

News Daily News

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Yael L. Maxwell

January 29, 2018

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Yael L. Maxwell

January 09, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Michael O'Riordan

December 05, 2017

News Daily News

Genetic Study Hints at Role of Lipids in AAA Risk

Michael O'Riordan

November 30, 2017

News Conference News AHA 2017

Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY

Michael O'Riordan

November 16, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

Advertisement

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Cardiovascular Disease and Risk Factors Increasing Among Patients Undergoing Noncardiac Surgery

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Genetic Study Hints at Role of Lipids in AAA Risk

Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Statins and Diabetes: Causal Link Reinforced in New Analysis

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Evolocumab Not Cost-Effective at Current List Price

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content